Interestingly, this polymorphism, along with five others within VDR or CYP24A1, was included in the SNP panel, which together with the clinical predictors strengthened the sensitivity of the test for 10-year prostate cancer-specific mortality from 91.4% to 94.3% (OR: 2.9, 95% CI: 4.0%, 15.5%, p = 0.2) [71]. Here, CYP24A1 is linked to prostate cancer.